Skip to main content
. 2022 Dec 5;11(6):487–494. doi: 10.4103/EUS-D-22-00014

Table 1.

Baseline characteristics of the study population

Characteristic Total (n=34)
Demographic
 Gender (female), n (%) 17 (50.0)
 Age (years), median (IQR) 76 (67-83)
 Study period (2010-2017), n (%) 15 (44.1)
 Study period (2018-2020), n (%) 19 (55.9)
Primary tumor, n (%)
 Proven pathology 28 (82.4)
 Perihilar cholangiocarcinoma 25 (73.5)
 Gallbladder carcinoma 9 (26.5)
Tumor staging, n (%)
 Bismuth-Corlette type I 2 (5.9)
 Bismuth-Corlette type II 8 (23.5)
 Bismuth-Corlette type IIIa 4 (11.8)
 Bismuth-Corlette type IIIb 3 (8.8)
 Bismuth-Corlette type IV 17 (50.0)
 Distant metastasis 24 (70.6)
 Ascites 9 (26.5)
 Portal hypertension 2 (5.9)
Serum laboratory test, median (IQR)
 Total bilirubin (μmol/L) 226 (121-299)
 C reactive protein (mg/L) 71 (18-164)
Previous interventions
 Previous ERCP, n (%) 24 (70.6)
 Number of previous ERCP, mean (range) 2.4 (1-5)
 Number of biliary stents, mean (range) 1.45 (0-3)
 Percutaneous drainage, n (%) 2 (5.9)
Indication for biliary drainage, n (%)
 Jaundice 22 (64.7)
 Sepsis without jaundice 2 (5.9)
 Cholangitis 10 (29.4)
Indication for EUS-HGS, n (%)
 ERCP failure 22 (64.7)
 Duodenal stricture 8 (23.5)
 Altered anatomy 2 (5.9)
 Isolated left hepatic duct dilation 2 (5.9)
Oncological status, n (%)
 Fit for chemotherapy 22 (64.7)
 Previous chemotherapy 14 (41.2)

IQR: Interquartile range, EUS-HGS: EUS-guided hepaticogastrostomy

HHS Vulnerability Disclosure